A Selective FGFR1/2 PROTAC Degrader with Antitumor Activity.
Kong Y, Zhao X, Wang Z, Yuan S, Chen S, Lou S, Ma S, Li Y, Wang X, Ge Y, Li G, Yang H, Zhao M, Li D, Zhang H, Tan W, Wang J.
Kong Y, et al. Among authors: tan w.
Mol Cancer Ther. 2024 Jun 10:OF1-OF11. doi: 10.1158/1535-7163.MCT-23-0719. Online ahead of print.
Mol Cancer Ther. 2024.
PMID: 38853423